Titan Pharmaceuticals (TTNP)
(Delayed Data from NSDQ)
$6.94 USD
+0.42 (6.45%)
Updated Jun 11, 2024 12:31 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Titan Pharmaceuticals, Inc. [TTNP]
Reports for Purchase
Showing records 41 - 60 ( 113 total )
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q16 Recap - Waiting for May 27th (Expecting Approval)
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q15 Recap - Probuphine PDUFA Approaching Feb. 27
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.